We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: clinical trial
MedXY News
EnglishTag

clinical trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority
Gastroenterologyclinical trialLaparoscopy

Long-Term Parity in Adhesiolysis: 5-Year Results from the LASSO Randomized Trial Challenge Laparoscopic Superiority

By MedXY|Feb 19, 2026

The 5-year follow-up of the LASSO randomized clinical trial demonstrates that while laparoscopic adhesiolysis offers short-term recovery benefits, it provides no significant long-term advantage over open surgery regarding SBO recurrence, in

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants
Critical Careclinical trialNeonatology

Automated Oxygen Control vs. Manual Care: Large-Scale Trial Finds No Difference in Clinical Outcomes for Extremely Preterm Infants

By MedXY|Feb 14, 2026

A multicenter randomized trial of 1,082 extremely preterm infants found that automated FiO2 control did not significantly reduce death or major morbidities compared to manual titration, though it remains a safe labor-saving tool for neonata

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints
Gastroenterologyclinical trialGastroparesis

Metopimazine Mesylate (NG101) in Gastroparesis: Navigating the Complexities of Nausea Management and Trial Endpoints

By MedXY|Feb 3, 2026

This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial
Internal Medicinechronic coughclinical trial

Oral Nalbuphine Significantly Reduces Cough Frequency in Patients with Idiopathic Pulmonary Fibrosis: Results from the CORAL Trial

By MedXY|Jan 25, 2026

The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi

Cast Immobilization is Non-inferior to Surgery for Unstable Weber B Ankle Fractures: Results from the SUPER-FIN Trial
Emergency Medicineclinical trialorthopedics

Cast Immobilization is Non-inferior to Surgery for Unstable Weber B Ankle Fractures: Results from the SUPER-FIN Trial

By MedXY|Jan 21, 2026

The SUPER-FIN randomized trial reveals that cast immobilization is a viable, non-inferior alternative to surgery for unstable Weber B ankle fractures with a congruent mortise, leading to fewer complications and avoiding unnecessary hardware

Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders
Neurologychronic low back painclinical trial

Graded Sensorimotor Retraining for Chronic Low Back Pain: Clinical Efficacy and the Search for Treatment Responders

By MedXY|Jan 16, 2026

The RESOLVE trial demonstrates that graded sensorimotor retraining provides modest pain relief for chronic low back pain. A secondary analysis reveals that these benefits are consistent across most patient subgroups, suggesting that the int

Beyond the Hospital Walls: Can Prospective Audit and Feedback Solve the Discharge Antibiotic Dilemma?
Infectious Diseasesantibiotic stewardshipclinical trial

Beyond the Hospital Walls: Can Prospective Audit and Feedback Solve the Discharge Antibiotic Dilemma?

By MedXY|Jan 16, 2026

A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting th

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial
newsclinical trialoropharyngeal cancer

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

By MedXY|Jan 14, 2026

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer
newsadjuvant chemotherapycapecitabine

A Decadel Leap: TCX Regimen Outperforms Standard TAC in 10-Year Survival for High-Risk HER2-Negative Breast Cancer

By MedXY|Jan 14, 2026

A 10-year randomized trial reveals that replacing anthracyclines with capecitabine (TCX) significantly improves overall survival and reduces toxicity compared to the standard TAC regimen in high-risk, HER2-negative breast cancer patients.

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis
newsclinical trialCost-Effectiveness

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

By MedXY|Jan 13, 2026

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its hi

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights
newsclinical trialdesmoid tumors

Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

By MedXY|Jan 13, 2026

This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise

Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?
Diabetes & Endocrinologyclinical trialGlycemic Control

Resveratrol and Type 2 Diabetes: Does the Red Wine Compound Really Control Blood Sugar?

By MedXY|Jan 11, 2026

A rigorous clinical trial reveals that five weeks of resveratrol supplementation does not improve blood sugar, GLP-1 levels, or gastric emptying in patients with type 2 diabetes.

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial
Clinical UpdatesatezolizumabBCG

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

By MedXY|Jan 9, 2026

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
Gastroenterologyclinical trialimmunotherapy

HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation

By MedXY|Jan 8, 2026

A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management
Infectious DiseasesAntimicrobial Resistanceclinical trial

Oral Zoliflodacin Proves Non-Inferior to Standard Dual Therapy for Gonorrhoea: A Milestone in Antimicrobial Resistance Management

By MedXY|Jan 7, 2026

This phase 3 trial demonstrates that oral zoliflodacin is a viable, non-inferior alternative to ceftriaxone plus azithromycin for treating uncomplicated urogenital gonorrhoea, offering a critical solution to rising antibiotic resistance.

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial
newsclinical trialmajor depressive disorder

Adjunctive Omega-3 Supplementation Does Not Improve Pediatric Major Depressive Disorder: Insights from a Multi-Center Randomized Trial

By MedXY|Jan 6, 2026

A multi-center randomized clinical trial involving 257 youths found that adjunctive omega-3 fatty acids (1.5 g/d) did not outperform placebo in treating moderate-to-severe pediatric major depressive disorder, despite high adherence and conc

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial
newsAcral Melanomaclinical trial

Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial

By MedXY|Jan 6, 2026

The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial
Clinical Updatesclinical trialDocetaxel

Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial

By MedXY|Jan 5, 2026

CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution
Infectious Diseasesclinical trialcolchicine

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

By MedXY|Jan 1, 2026

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients su

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT
Diabetes & Endocrinologyclinical trialendocrinology

Selenium Supplementation Fails to Improve Remission or Quality of Life in Graves’ Hyperthyroidism: Findings from the GRASS RCT

By MedXY|Jan 1, 2026

The GRASS trial, a double-blind multi-centre RCT, found that adding 200 µg of selenium daily to standard antithyroid drug therapy does not increase remission rates or improve quality of life in patients with newly diagnosed Graves’ hy

Prev
3 / 10
12345…10
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities